Transforming growth factor-β, transforming growth factor-β receptor II, and p27(Kip1) expression in nontumorous and neoplastic human pituitaries

American Journal of Pathology

Volumn 151, Issue 2, 1997, Pages 509-519

  Jin, Long ^a   Qian, Xiang ^a   Kulig, Elzbieta ^a   Sanno, Naoko ^b   Scheithauer, Bernd W ^a   Kovacs, Kaiman ^b   Young Jr , William F ^a   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROTEIN P27; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CARCINOGENESIS; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA; CARCINOMA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROTUBULE-ASSOCIATED PROTEINS; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 0030840987     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. 3 cells. Mol Endocrinol 1991, 5:1716-1722
2. Burns G, Sarkar DK: Transforming growth factor β 1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen. Endocrinology 1993, 133:1444-1449
3. Pastoric M, De A, Boyadjieva N, Vale W, Sarkar DK: Reduction in the expression and action of transforming growth factor β1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Cancer Res 1995, 55:4892-4898
4. Qian X, Jin L, Lloyd RV: Expression and regulation of transforming growth factor β1 in cultured normal and neoplastic rat pituitary cells. Endocr Pathol 1996, 7:77-90
5. Qian X, Jin L, Grande JP, Lloyd RV: Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996, 137:3051-3060
6. Fujiwara K, Ikeda H, Yoshimoto J: Immunohistochemical demonstration of transforming growth factor-β-1 in human pituitary adenomas. Brain Pathol 1994, 4:451
7. Lloyd RV, Jin L, Qian X: Transforming growth factor β 1 (TGF-β1) and the TGF-β regulated protein p27 in human and rodent pituitaries. Endocr Pathol 1995, 6:371-372 (Abstract)
8. Ebner R, Chen H, Shum L, Lawler S, Lee AL, Zioncheck TF, Lopez AR, Derynck R: Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science 1993, 260:1334-1348
9. Choi ME, Kim EG, Huang Q, Ballermann BJ: Rat mesengeal cell hypertrophy in response to transforming growth factor-β 1. Kidney Int 1993, 44:948-958
10. Wang X-F, Un HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA: Expression cloning and characterization of the TGF-β type III receptor. Cell 1991, 67:797-805
11. Sim L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F, Brattain MG; Expression of transforming growth factor-β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994, 269:26449-26455
12. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB: Genetic changes in the transforming growth factor-β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994, 91:8772-8776
13. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1996, 268:1336-1338
14. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmander J, Vellucci VF, Reiss M: Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous cell carcinoma cells. Cancer Res 1995, 55:3982-3987
15. Fujiwara K, Ikeda H, Yoshimoto T: Immunohistochemical demonstration of TGF-β receptor type II in human pituitary adenoma. Acta Histochem (Jena) 1995, 97:445-454
16. Alexander JM, Bikkal HA, Zenos NT, Lans ER Jr, Klibanski A: Tumorspecific expression and alternate splicing of messenger ribonucleic acid encoding actin/transforming group factor-β receptors in human pituitary adenomas. J Clin Endocrinol Metab 1996, 81:783-790
17. Massague J, Polyak K: Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 1995, 5:91-96
18. Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582
19. klp1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
20. klp1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22
21. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74
22. klp1 in C3H10T 1/2 mouse fibroblasts. Cancer Res 1995, 55:1413-1416
23. Thapar K, Kovacs K, Scheithauer BW, Morris D, et al: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1994, 35:1012-1017
24. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvatz E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schvene WC: Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997 (in press)
25. Jin L, Scheithauer BW, Young WF Jr, Davis PH, Klee GG, Lloyd RV: Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Am J Pathol 1996, 148:2057-2066
26. Jin L, Chandler WF, Smart JB, England BG, Lloyd RV: Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression. J Clin Endocrinol Metab 1993, 76:728-735
27. Kao PC, Jians N-S, Carpenter PC: Human corticotropin (ACTH) radioimmunoassay with synthetic 1-24 ACTH. Clin Chem 1979, 25: 1267-1273
28. Lloyd RV, Iacangelo A, Eiden LE, Cano M, Jin L, Grimes M: Chromogranins A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues, Lab Invest 1989, 60:548-556
29. Panoskaltsis-Mortari A, Buoy RP: In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. BioTechniques 1995, 18:300-307
30. Garrigue-Anter L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M: Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer, Lab Invest 1996, 75:263-272
31. klp1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
32. Toyoshima H, Hunter T: p27, a novel inhibitor of G, cyclin-Cdk protein kinase activity is related to p21. Cell 1994, 78:67-74
33. klp1 expression in endocrine and other tumors, Am J Pathol 1997, 150:1-7
34. klp1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 1996, 85:707-720
35. klp1. Cell 1996, 85:721-732
36. klp1-deficient mice. Cell 1996, 85: 733-744
37. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chuu V, Yew PR, Draetta GF, Rulfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27, Science 1995, 269:682-685
38. kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995, 55:1206-1210
39. kip1 chromosomal mapping to 12p 12-12p13 and absence of mutations in human tumors. Cancer Res 1995, 55: 1211-1214
40. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Wakayami T, Tekeuchi S, Halta Y, Simpson J, Wilcznski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 1995, 35: 2266-2269
41. Spirin KS, Simpson JF, Takenchi S, Kawamata N, Miller CW, Koeffler HP: p27/kip1 mutation found in breast cancer. Cancer Res 1996, 56:2400-2404
42. kip1. J Clin Invest 1996, 97:1983-1988
43. klp1 in C3H 10 T1/2 mouse fibroblasts. Cancer Res 1995, 55: 1413-1416
44. Poon RYC, Toyoshima H, Hunter T: Redistribution of the CDK inhibitor p27 between different cyclin CDK complexes in the mouse fibroblast cell cycle and in cells arrested with levostatin or ultraviolet irradiation. Mol Biol Cell 1995, 6:1197-1213
45. klp1 on resistance of tumor cells to anti-cancer agents, Nature Med 1996, 2:1204-1210
46. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677
47. klp1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997, 3:222-225
48. klp1 protein: prognostic implications in primary breast cancer. Nature Med 1997, 3:227-230
49. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive cole-rectal carcinomas. Nature Med 1997, 3:231-234